期刊
CURRENT OPINION IN VIROLOGY
卷 52, 期 -, 页码 182-191出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2021.12.003
关键词
-
类别
资金
- Swiss National Science Foundation (SNSF) [PZ00P3_174108, CRSII5_189957]
- Swiss National Science Foundation (SNF) [CRSII5_189957, PZ00P3_174108] Funding Source: Swiss National Science Foundation (SNF)
The rise in antimicrobial resistance has led to a renewed interest in phage therapy, but further research is needed to demonstrate its therapeutic potential. Advances in synthetic biology and genetic engineering can overcome inherent limitations of natural phages, improving their antibacterial efficacy and expanding their applicability.
The alarming rise in antimicrobial resistance coupled with a lack of innovation in antibiotics has renewed interest in the development of alternative therapies to combat bacterial infections. Despite phage therapy demonstrating success in various individual cases, a comprehensive and unequivocal demonstration of the therapeutic potential of phages remains to be shown. The co-evolution of phages and their bacterial hosts resulted in several inherent limitations for the use of natural phages as therapeutics such as restricted host range, moderate antibacterial efficacy, and frequent emergence of phage-resistance. However, these constraints can be overcome by leveraging recent advances in synthetic biology and genetic engineering to provide phages with additional therapeutic capabilities, improved safety profiles, and adaptable host ranges. Here, we examine different ways phages can be engineered to deliver heterologous therapeutic payloads to enhance their antibacterial efficacy and discuss their versatile applicability to combat bacterial pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据